Clinical Research Directory
Browse clinical research sites, groups, and studies.
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Sponsor: Sardocor Corp.
Summary
It is believed that targeted SERCA2a enzyme replacement in HFrEF patients will correct defective intracellular Ca2+ hemostasis, resulting in improved cardiac contractile function and energetics which will, in turn, translate to improved clinical outcomes. Additionally, it is hypothesized that correcting SERCA2a dysfunction will also improve coronary blood flow through correction of the impaired endothelium-dependent nitric oxide-mediated vasodilatation observed in heart failure.
Official title: A Phase 1/2 Trial of the Safety and Efficacy of SRD-001 (AAV1/SERCA2a) in Subjects With Heart Failure With Reduced Ejection Fraction
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
57
Start Date
2021-09-23
Completion Date
2028-12
Last Updated
2024-03-26
Healthy Volunteers
No
Conditions
Interventions
SRD-001
AAV1/SERCA2a
Placebo
SRD-001 matching placebo
Locations (5)
San Diego Cardiac Center
San Diego, California, United States
University of California, San Francisco
San Francisco, California, United States
Washington University in Saint Louis
St Louis, Missouri, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
University of Washington Medicine
Seattle, Washington, United States